Zentalis Pharmaceuticals, Inc. – NASDAQ:ZNTL

Zentalis Pharmaceuticals stock price today

$1.59
-1.47
-48.04%
Financial Health
0
1
2
3
4
5
6
7
8
9

Zentalis Pharmaceuticals stock price monthly change

-22.92%
month

Zentalis Pharmaceuticals stock price quarterly change

-22.92%
quarter

Zentalis Pharmaceuticals stock price yearly change

-80.03%
year

Zentalis Pharmaceuticals key metrics

Market Cap
213.79M
Enterprise value
N/A
P/E
-3.84
EV/Sales
N/A
EV/EBITDA
N/A
Price/Sales
N/A
Price/Book
2.33
PEG ratio
0.11
EPS
-3.36
Revenue
N/A
EBITDA
-178.49M
Income
-218.90M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Zentalis Pharmaceuticals stock price history

Zentalis Pharmaceuticals stock forecast

Zentalis Pharmaceuticals financial statements

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL): Profit margin
Jun 2023 0 -112.52M
Sep 2023 0 -55.52M
Dec 2023 2.10M -60.91M -2895.29%
Mar 2024 40.56M 10.06M 24.82%
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL): Analyst Estimates
Mar 2024 40.56M 10.06M 24.82%
Sep 2025 0 -57.32M
Oct 2025 40.56M -65.67M -161.92%
Dec 2025 40.56M -65.67M -161.92%
  • Analysts Price target

  • Financials & Ratios estimates

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL): Debt to assets
Jun 2023 621444000 98.16M 15.8%
Sep 2023 585715000 103.81M 17.73%
Dec 2023 562027000 124.63M 22.18%
Mar 2024 557479000 98.70M 17.71%
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL): Cash Flow
Jun 2023 -79.27M 72.93M 236.62M
Sep 2023 -38.66M -117.45M 309K
Dec 2023 -40.59M -42.06M 0
Mar 2024 -51.97M 61.54M 7K

Zentalis Pharmaceuticals alternative data

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL): Employee count
Aug 2023 156
Sep 2023 156
Oct 2023 156
Nov 2023 156
Dec 2023 156
Jan 2024 156
Feb 2024 156
Apr 2024 124
May 2024 124
Jun 2024 124
Jul 2024 124

Zentalis Pharmaceuticals other data

47.04% -52.96%
of ZNTL is owned by hedge funds
24.86M -39.46M
shares is hold by hedge funds

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL): Insider trades (number of shares)
Period Buy Sel
Nov 2023 22000 0
Feb 2024 0 28862
May 2024 0 12953
Oct 2024 0 1603
Transaction Date Insider Security Shares Price per share Total value Source
Sale
VULTAGGIO VINCENT officer: Principal Accounting O..
Common Stock 1,603 $3.18 $5,098
Sale
GALLAGHER CAM director, officer: President, I..
Common Stock 9,597 $11.98 $114,972
Sale
HAUSMAN DIANA officer: Chief Medical Officer
Common Stock 3,356 $12.62 $42,353
Sale
EPPERLY MELISSA B, officer: Chief Financial Officer
Common Stock 2,573 $11.44 $29,435
Sale
GALLAGHER CAM director, officer: President
Common Stock 1,173 $11.44 $13,419
Sale
LACKNER MARK officer: Chief Scientific Officer
Common Stock 1,585 $11.54 $18,291
Sale
PAUL ANDREA officer: Chief Legal Officer
Common Stock 3,310 $11.54 $38,197
Sale
GALLAGHER CAM director, officer: President
Common Stock 11,552 $11.54 $133,310
Sale
EPPERLY MELISSA B, officer: Chief Financial Officer
Common Stock 8,669 $11.54 $100,040
Purchase
BLACKWELL KIMBERLY director, officer: Chief Execut..
Common Stock 5,000 $10.29 $51,450
Thursday, 12 December 2024
globenewswire.com
Monday, 2 December 2024
globenewswire.com
Thursday, 21 November 2024
globenewswire.com
Friday, 1 November 2024
globenewswire.com
Monday, 7 October 2024
gurufocus.com
Tuesday, 17 September 2024
zacks.com
Monday, 16 September 2024
prnewswire.com
benzinga.com
globenewswire.com
Monday, 9 September 2024
globenewswire.com
Tuesday, 3 September 2024
globenewswire.com
Monday, 26 August 2024
zacks.com
Monday, 19 August 2024
businesswire.com
accesswire.com
Sunday, 18 August 2024
accesswire.com
accesswire.com
Saturday, 17 August 2024
accesswire.com
Friday, 16 August 2024
accesswire.com
accesswire.com
Thursday, 15 August 2024
globenewswire.com
accesswire.com
accesswire.com
Wednesday, 14 August 2024
accesswire.com
accesswire.com
accesswire.com
Tuesday, 13 August 2024
accesswire.com
Monday, 12 August 2024
accesswire.com
accesswire.com
accesswire.com
Sunday, 11 August 2024
accesswire.com
  • What's the price of Zentalis Pharmaceuticals stock today?

    One share of Zentalis Pharmaceuticals stock can currently be purchased for approximately $1.59.

  • When is Zentalis Pharmaceuticals's next earnings date?

    Unfortunately, Zentalis Pharmaceuticals's (ZNTL) next earnings date is currently unknown.

  • Does Zentalis Pharmaceuticals pay dividends?

    No, Zentalis Pharmaceuticals does not pay dividends.

  • How much money does Zentalis Pharmaceuticals make?

    Zentalis Pharmaceuticals has a market capitalization of 213.79M.

  • What is Zentalis Pharmaceuticals's stock symbol?

    Zentalis Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "ZNTL".

  • What is Zentalis Pharmaceuticals's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Zentalis Pharmaceuticals?

    Shares of Zentalis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Zentalis Pharmaceuticals's key executives?

    Zentalis Pharmaceuticals's management team includes the following people:

    • Dr. Anthony Y. Sun M.D. Pres, Chief Executive Officer & Executive Chairman(age: 53, pay: $957,280)
    • Dr. Kevin D. Bunker Ph.D. Chief Operating Officer(age: 52, pay: $699,500)
    • Ms. Alexis M. Pinto J.D. Chief Legal Officer & Sec.(age: 58, pay: $491,130)
    • Mr. Cam S. Gallagher M.B.A. Sec. & Director(age: 55, pay: $467,150)
  • How many employees does Zentalis Pharmaceuticals have?

    As Jul 2024, Zentalis Pharmaceuticals employs 124 workers.

  • When Zentalis Pharmaceuticals went public?

    Zentalis Pharmaceuticals, Inc. is publicly traded company for more then 5 years since IPO on 3 Apr 2020.

  • What is Zentalis Pharmaceuticals's official website?

    The official website for Zentalis Pharmaceuticals is zentalis.com.

  • Where are Zentalis Pharmaceuticals's headquarters?

    Zentalis Pharmaceuticals is headquartered at 1359 Broadway, New York, NY.

  • How can i contact Zentalis Pharmaceuticals?

    Zentalis Pharmaceuticals's mailing address is 1359 Broadway, New York, NY and company can be reached via phone at +212 4333791.

Zentalis Pharmaceuticals company profile:

Zentalis Pharmaceuticals, Inc.

zentalis.com
Exchange:

NASDAQ

Full time employees:

124

Industry:

Biotechnology

Sector:

Healthcare

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.

1359 Broadway
New York, NY 10018

CIK: 0001725160
ISIN: US98943L1070
CUSIP: 98943L107